Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 50 of 173 results for copyright

  1. Chemotherapy dose standardisation: NICE position statement

    ensure that NICE processes, tools and resources are suitably aligned. Copyright © NICE 2018. All rights reserved. Subject to Notice of...

  2. NICE health technology evaluations: the manual (PMG36)

    This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website.

  3. Terms and conditions

    Terms and conditions for the National Institute for Health and Care Excellence

  4. Freedom of Information

    Freedom of Information

  5. Freedom of information publication scheme

    of health, public health and social care. View our guidance Copyright The copyright in the material listed in this...

  6. Core standards (non-Agents)

    right to provide or which it has reasonable grounds to believe infringes copyright; or is defamatory, obscene, unlawful or otherwise...

  7. Core standards (Agents)

    Purchasing framework core service requirements

  8. Ulcerative colitis: management (NG130)

    This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

  9. Guide to the processes of technology appraisal (PMG19)

    Guide to the processes of technology appraisal

  10. Intravenous fluid therapy in adults in hospital (CG174)

    This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.

  11. The social care guidance manual (PMG10)

    The social care guidance manual

  12. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

  13. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

  14. Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

    Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

  15. Interventional procedures programme manual (PMG28)

    Interventional procedures programme manual

  16. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  17. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

  18. Healthy start vitamins: special report on cost effectiveness (ECD5)

    Healthy start vitamins: special report on cost effectiveness

  19. Suture fixation of acute disruption of the distal tibiofibular syndesmosis (IPG521)

    Evidence-based recommendations on suture fixation of acute disruption of the distal tibiofibular syndesmosis. This involves threading a suture through a tunnel made in the bones (tibia and fibula) and tying the ends together to fix the joint.

  20. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

  21. Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (IPG523)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.

  22. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

  23. Smoking: reducing and preventing tobacco use (QS82)

    This quality standard covers reducing and preventing tobacco use in adults, young people and children. It includes interventions to discourage people from taking up smoking, tobacco control strategies and smokefree policies. It is particularly relevant to local authorities, schools and colleges, employers and NHS service providers. It describes high-quality care in priority areas for improvement.

  24. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

  25. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  26. Interim methods guide for developing service guidance 2014 (PMG8)

    Interim methods guide for developing service guidance 2014

  27. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

  28. Interim methods guide for developing good practice guidance (PMG15)

    Interim methods guide for developing good practice guidance

  29. Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (IPG482)

    Evidence-based recommendations on extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.

  30. Insertion of a magnetic bead band for faecal incontinence (IPG483)

    Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.

  31. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)

    Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.

  32. Behaviour change: individual approaches (PH49)

    This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.

  33. Negative pressure wound therapy for the open abdomen (IPG467)

    Evidence-based recommendations on negative pressure wound therapy for the open abdomen. This involves using a small pump to remove infected material, stop fluid escaping and help the wound heal.

  34. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013

  35. Interim clinical guideline surveillance process and methods guide 2013 (PMG16)

    Interim clinical guideline surveillance process and methods guide 2013

  36. Insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction (IPG457)

    Evidence-based recommendations on insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction. This involves making the titanium implants specially to fit the person using a model of their face.

  37. Insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction (IPG449)

    Evidence-based recommendations on insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction. This involves inserting titanium implants to replace broken bones in the face as part of orofacial reconstruction.

  38. Insertion of endobronchial valves for persistent air leaks (IPG448)

    Evidence-based recommendations on insertion of endobronchial valves for treatment of persistent air leaks. This involves inserting valves into the airways to reduce or stop air leaks so the rest of the lung can function normally.

  39. Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)

    Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.

  40. Irreversible electroporation for treating renal cancer (IPG443)

    Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.

  41. Irreversible electroporation for treating liver metastases (IPG445)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

  42. Laparoscopic gastric plication for the treatment of severe obesity (IPG432)

    Evidence-based recommendations on laparoscopic gastric plication for the treatment of morbid obesity. This involves folding the stomach in on itself and stitching it together to reduce its volume.

  43. The NICE public health guidance development process (third edition) (PMG5)

    The NICE public health guidance development process (third edition)

  44. Methods for the development of NICE public health guidance (third edition) (PMG4)

    Methods for the development of NICE public health guidance (third edition)

  45. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    Evidence summaries: unlicensed and off-label medicines – Interim process statement

  46. Good practice guidance – Interim process statement (PMG3)

    Good practice guidance – Interim process statement

  47. Endovascular stent insertion for intracranial atherosclerotic disease (IPG429)

    Evidence-based recommendations on endovascular stent insertion for intracranial atherosclerotic disease. This involves inflating a balloon catheter inserted into an artery in the arm or leg, and positioning a stent in the narrowing to maintain improved blood flow.

  48. Evidence summaries: new medicines – Interim process statement (PMG1)

    Evidence summaries: new medicines – Interim process statement

  49. Percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation (IPG427)

    Evidence-based recommendations on percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation. This involves using a probe attached to a balloon catheter to freeze tissue in one of the chambers on the left side of the heart.

  50. Focal therapy using cryoablation for localised prostate cancer (IPG423)

    Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.